Peter M Strumph insider trades: Nile Therapeutics (NLTX) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Peter reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 12, 2008 | NLTX | ↑ Buy | 3,000 | $0.86 | $3K | Direct | Dec 12, 2008 (0d) |
| Dec 11, 2008 | NLTX | ↑ Buy | 3,580 | $0.60 | $2K | Direct | Dec 12, 2008 (1d) |
| Apr 14, 2008 | NILT.OB | ↑ Buy | 1,000 | $4.70 | $5K | Direct | Apr 16, 2008 (2d) |
| Apr 14, 2008 | NILT.OB | ↑ Buy | 200 | $4.70 | $940 | By Daughter | Apr 16, 2008 (2d) |
| Apr 14, 2008 | NILT.OB | ↑ Buy | 200 | $4.70 | $940 | By Son | Apr 16, 2008 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Peter M Strumph's insider trades
Peter M Strumph is Chief Executive Officer at Nile Therapeutics (NLTX). Since Apr 14, 2008, Peter has reported 5 open-market purchases worth $11K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (6 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NLTX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.